Treatment-related regret is common in localized prostate cancer

Key clinical point: Treatment-related regret is common in patients with clinically localized prostate cancer. Patients undergoing surgery reported a significantly higher regret vs those undergoing radiotherapy or active surveillance.

Major finding: Overall treatment-related regret at 5 years was 13%. Treatment-related regret with surgery, radiotherapy, and active surveillance was 16%, 11%, and 7%, respectively. Patients who underwent surgery had a higher likelihood of regret than those who underwent active surveillance (adjusted odds ratio [aOR], 2.40; P < .001) or radiotherapy (aOR, 1.57; P = .01).

Study details: An observational study of 2,072 patients with clinically localized prostate cancer between 2011 and 2012.

Disclosures: This work was supported by Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, and National Cancer Institute. The authors reported receiving personal fees and grants outside this work.

Source: Wallis CJD et al. JAMA Oncol. 2021 Nov 18. doi: 10.1001/jamaoncol.2021.5160.

Key clinical point: Treatment-related regret is common in patients with clinically localized prostate cancer. Patients undergoing surgery reported a significantly higher regret vs those undergoing radiotherapy or active surveillance.

Major finding: Overall treatment-related regret at 5 years was 13%. Treatment-related regret with surgery, radiotherapy, and active surveillance was 16%, 11%, and 7%, respectively. Patients who underwent surgery had a higher likelihood of regret than those who underwent active surveillance (adjusted odds ratio [aOR], 2.40; P < .001) or radiotherapy (aOR, 1.57; P = .01).

Study details: An observational study of 2,072 patients with clinically localized prostate cancer between 2011 and 2012.

Disclosures: This work was supported by Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, and National Cancer Institute. The authors reported receiving personal fees and grants outside this work.

Source: Wallis CJD et al. JAMA Oncol. 2021 Nov 18. doi: 10.1001/jamaoncol.2021.5160.

Key clinical point: Treatment-related regret is common in patients with clinically localized prostate cancer. Patients undergoing surgery reported a significantly higher regret vs those undergoing radiotherapy or active surveillance.

Major finding: Overall treatment-related regret at 5 years was 13%. Treatment-related regret with surgery, radiotherapy, and active surveillance was 16%, 11%, and 7%, respectively. Patients who underwent surgery had a higher likelihood of regret than those who underwent active surveillance (adjusted odds ratio [aOR], 2.40; P < .001) or radiotherapy (aOR, 1.57; P = .01).

Study details: An observational study of 2,072 patients with clinically localized prostate cancer between 2011 and 2012.

Disclosures: This work was supported by Patient-Centered Outcomes Research Institute, Agency for Healthcare Research and Quality, and National Cancer Institute. The authors reported receiving personal fees and grants outside this work.

Source: Wallis CJD et al. JAMA Oncol. 2021 Nov 18. doi: 10.1001/jamaoncol.2021.5160.